1. Home
  2. IPHA

as of 02-25-2026 4:00pm EST

$1.74
$0.00
0.00%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Founded: 1999 Country:
France
France
Employees: N/A City: N/A
Market Cap: 169.6M IPO Year: N/A
Target Price: $5.00 AVG Volume (30 days): 20.9K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $1.57 - $2.63 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 28.31% Revenue Growth (next year): -1.93%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: